Biography
Biography: J. T. Lin
Abstract
This presentation consists of the historical review of ophthalmic laser technologies (1987 to 2016) and the recent developments of corneal cross-linking (CXL). The first human trial of PRK conducted in 1987 was based upon the IBM patent (UV laser for organic tissue ablation) and obtained the FDA clearance in 1995 (and LASIK in 2002). The flying-spot scanning technology for customized corneal reshaping was first proposed by Dr. J.T. Lin in 1992 (US patent). During 1995-1999, various laser systems/procedures were developed including: LTK (using Ho:YAG), DTK (using diode laser), RF and CK for hyperopia corrections; solid state lasers YAG-213 nm (for PRK), Mini-Excimer for PRK etc. Technologies developed in the 2000s include: eye-tracking device, microkeratome, Elevation map, topograpy-guided LASIK, wavefront for customized LASIK; presbyopia treatment using accommodative IOL, SEB (Schachar) and laser scleral-ablation (Lin); and femto-second lasers (for cornea flap, cataract, and stroma lens cut). In the recent years, UV-light riboflavin-activated corneal cross-linking (CXL) has beeen explored for various combined procedures including CXL-femto-laser, CXL-IOL, CXL-corneal-ring, CXL-sclera, and CXL-pediatric-myopes. The technical and clinical issues for CXL will be presented including: the optimal dose for new protocols, and riboflavin diffusion methods such as epi-off, epi-on, direct introduction of riboflavin into the stroma (pocket technique, ring technique, needle technique), and enrichment of riboflavin in the stroma by iontophoresis. Optimal CXL based on a dynamic theory will be presented for the first time.